Actinium Pharmaceuticals, Inc. (ATNM)

Targeted Therapies for Patients with Unmet Needs

Actinium is developing a pipeline Antibody Radiation Conjugates for targeted conditioning and combination therapies

Actinium to Announce Interim Results from Pivotal Phase 3 SIERRA Trial on Conference Call Scheduled for Monday, October 28th

Conference call and webcast scheduled to start at 12:00 PM ET on Monday, October 28, 2019

The Science Behind Antibody Radiation Conjugates

Targeted Conditioning and ARC Pipeline

SIERRA: Pivotal Phase 3 Clinical Trial of Iomab-B

News

Featured Video

A Phase III Trial Evaluating Iomab-B Prior to HCT in Relapsed/Refractory AML

$A Phase III Trial Evaluating Iomab-B Prior to HCT in Relapsed/Refractory AML$

Tweets by ActiniumPharma

Investor Relations

Investor Presentation

Contact Us